Parkin-mediated ubiquitination of mutant glucocerebrosidase leads to competition with its substrates PARIS and ARTS

Orphanet Journal of Rare Diseases

Volumn 9, Issue 1, 2014, Pages

  Bendikov Bar, Inna ^a   Rapaport, Debora ^a   Larisch, Sarit ^b   Horowitz, Mia ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF HAIFA   (Israel)

Author keywords

Arts; Gaucher disease; Glucocerebrosidase; Paris; Parkinson disease

Indexed keywords

CASPASE 3; CASPASE 9; GLUCOSYLCERAMIDASE; PARKIN;

ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; CELL DEATH; CHILD; CLINICAL ARTICLE; DOWN REGULATION; ENZYME DEGRADATION; ENZYME SUBSTRATE; FEMALE; GAUCHER DISEASE; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MALE; MIDDLE AGED; OXIDATIVE PHOSPHORYLATION; PARKINSON DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SKIN FIBROBLAST; UBIQUITINATION; ANIMAL CELL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME STABILITY; NONHUMAN; PROTEIN INTERACTION;

APOPTOSIS; CASPASES; CELL LINE; DNA PRIMERS; FEMALE; GLUCOSYLCERAMIDASE; HUMANS; MALE; MUTATION; REAL-TIME POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; SEPTINS; SUBSTRATE SPECIFICITY; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84903788086     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-9-86     Document Type: Article

References (67)

1. Gaucher disease. Beutler E, Adv Genet 1995 32 17 49
2. Gaucher disease: multiple lessons from a single gene disorder. Beutler E, Acta Paediatr Suppl 2006 95 103 109 (Pubitemid 43739104)
3. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Ron I, Horowitz M, Hum Mol Genet 2005 14 2387 2398 (Pubitemid 41418000)
4. Unfolded protein response in Gaucher disease: from human to Drosophila. Maor G, Rencus-Lazar S, Filocamo M, Steller H, Segal D, Horowitz M, Orphanet J Rare Dis 2013 8 140
5. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R, N Engl J Med 2004 351 1972 1977 (Pubitemid 39447138)
6. Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Bembi B, Zambito Marsala S, Sidransky E, Ciana G, Carrozzi M, Zorzon M, Martini C, Gioulis M, Pittis MG, Capus L, Neurology 2003 61 99 101 (Pubitemid 36818755)
7. Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. Clark LN, Nicolai A, Afridi S, Harris J, Mejia-Santana H, Strug L, Cote LJ, Louis ED, Andrews H, Waters C, Ford B, Frucht S, Fahn S, Mayeux R, Ottman R, Marder K, Mov Disord 2005 20 100 103 (Pubitemid 40277515)
8. The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. Eblan MJ, Walker JM, Sidransky E, N Engl J Med 2005 352 728 731 author reply 728-731 (Pubitemid 40239226)
9. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Goker-Alpan O, Giasson BI, Eblan MJ, Nguyen J, Hurtig HI, Lee VM, Trojanowski JQ, Sidransky E, Neurology 2006 67 908 910 (Pubitemid 44394221)
10. Parkinsonism among Gaucher disease carriers. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E, J Med Genet 2004 41 937 940 (Pubitemid 40007255)
11. The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. Schlossmacher MG, Cullen V, Muthing J, N Engl J Med 2005 352 728 731 author reply 728-731 (Pubitemid 40239226)
12. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, Chen CM, Clark LN, Condroyer C, De Marco EV, Dürr A, Eblan MJ, Fahn S, Farrer MJ, Fung HC, Gan-Or Z, Gasser T, Gershoni-Baruch R, Giladi N, Griffith A, Gurevich T, Januario C, Kropp P, Lang AE, Lee-Chen GJ, Lesage S, et al. N Engl J Med 2009 361 1651 1661
13. The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. Zimran A, Neudorfer O, Elstein D, N Engl J Med 2005 352 728 731 author reply 728-731 (Pubitemid 40239226)
14. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Kalinderi K, Bostantjopoulou S, Paisan-Ruiz C, Katsarou Z, Hardy J, Fidani L, Neurosci Lett 2009 452 87 89
15. Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Lesage S, Anheim M, Condroyer C, Pollak P, Durif F, Dupuits C, Viallet F, Lohmann E, Corvol JC, Honore A, Rivaud S, Vidailhet M, Dürr A, Brice A, for the French Parkinson's Disease Genetics Study Group, Hum Mol Genet 2011 20 202 210
16. Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Seto-Salvia N, Pagonabarraga J, Houlden H, Pascual-Sedano B, Dols-Icardo O, Tucci A, Paisan-Ruiz C, Campolongo A, Anton-Aguirre S, Martin I, Muñoz L, Bufill E, Vilageliu L, Grinberg D, Cozar M, Blesa R, Lleó A, Hardy J, Kulisevsky J, Clarimón J, Mov Disord 2012 27 393 399
17. Neurological manifestations in patients with Gaucher disease and their relatives, it is just a coincidence? Giraldo P, Capablo JL, Alfonso P, Garcia-Rodriguez B, Latre P, Irun P, de Cabezon AS, Pocovi M, J Inherit Metab Dis 2011 34 781 787
18. beta-Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease. Moraitou M, Hadjigeorgiou G, Monopolis I, Dardiotis E, Bozi M, Vassilatis D, Vilageliu L, Grinberg D, Xiromerisiou G, Stefanis L, Michelakakis H, Mol Genet Metab 2011 104 149 152
19. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Neumann J, Bras J, Deas E, O'Sullivan SS, Parkkinen L, Lachmann RH, Li A, Holton J, Guerreiro R, Paudel R, Segarane B, Singleton A, Lees A, Hardy J, Houlden H, Revesz T, Wood NW, Brain 2009 132 1783 1794
20. Parkinson's disease: mechanisms and models. Dauer W, Przedborski S, Neuron 2003 39 889 909 (Pubitemid 37130207)
21. Parkinson's disease: genetics and pathogenesis. Shulman JM, De Jager PL, Feany MB, Annu Rev Pathol 2011 6 193 222
22. Staging of brain pathology related to sporadic Parkinson's disease. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E, Neurobiol Aging 2003 24 197 211 (Pubitemid 36007810)
23. Animal models of Parkinson's disease: a gateway to therapeutics? Le W, Sayana P, Jankovic J, Neurotherapeutics 2014 11 92 110
24. Nonmotor manifestations of Parkinson's disease. Simuni T, Sethi K, Ann Neurol 2008 64 Suppl 2 65 S80
25. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in Synucleinopathies. Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D, Cell 2011 146 37 52
26. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N, Nature 1998 392 605 608 (Pubitemid 28207717)
27. Association between early-onset Parkinson's disease and mutations in the parkin gene. Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denefle P, Wood NW, Agid Y, Brice A, French Parkinson's Disease Genetics Study Group, N Engl J Med 2000 342 1560 1567 (Pubitemid 30340501)
28. Parkin plays a role in sporadic Parkinson's disease. Dawson TM, Dawson VL, Neurodegener Dis 2014 13 69 71
29. Parkin: a multifaceted ubiquitin ligase. Moore DJ, Biochem Soc Trans 2006 34 749 753 (Pubitemid 44796412)
30. The PINK1/Parkin-mediated mitophagy is compromised by PD-associated mutations. Geisler S, Holmstrom KM, Treis A, Skujat D, Weber SS, Fiesel FC, Kahle PJ, Springer W, Autophagy 2010 6 871 878
31. Parkin-mediated K63-linked polyubiquitination: a signal for targeting misfolded proteins to the aggresome-autophagy pathway. Olzmann JA, Chin LS, Autophagy 2008 4 85 87
32. Parkin's substrates and the pathways leading to neuronal damage. Cookson MR, Neuromolecular Med 2003 3 1 13 (Pubitemid 37070578)
33. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, Troconso JC, Dawson VL, Dawson TM, Cell 2011 144 689 702
34. Parkin promotes degradation of the mitochondrial pro-apoptotic ARTS protein. Kemeny S, Dery D, Loboda Y, Rovner M, Lev T, Zuri D, Finberg JP, Larisch S, PLoS One 2012 7 38837
35. The role of parkin in familial and sporadic Parkinson's disease. Dawson TM, Dawson VL, Mov Disord 2010 25 Suppl 1 32 S39
36. Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease. Ron I, Rapaport D, Horowitz M, Hum Mol Genet 2010 19 3771 3781
37. Immunochemical analysis of the turnover of ubiquitin-protein conjugates in intact cells. Relationship to the breakdown of abnormal proteins. Hershko A, Eytan E, Ciechanover A, Haas AL, J Biol Chem 1982 257 13964 13970
38. Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. Bendikov-Bar I, Ron I, Filocamo M, Horowitz M, Blood Cells Mol Dis 2011 46 4 10
39. Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals. Tsuji S, Martin BM, Barranger JA, Stubblefield BK, LaMarca ME, Ginns EI, Proc Natl Acad Sci U S A 1988 85 2349 2352 (Pubitemid 24315889)
40. The mitochondrial ARTS protein promotes apoptosis through targeting XIAP. Gottfried Y, Rotem A, Lotan R, Steller H, Larisch S, EMBO J 2004 23 1627 1635 (Pubitemid 38579523)
41. X-linked Inhibitor of Apoptosis Protein promotes the degradation of its antagonist, the pro-apoptotic ARTS protein. Bornstein B, Edison N, Gottfried Y, Lev T, Shekhtman A, Gonen H, Rajalingam K, Larisch S, Int J Biochem Cell Biol 2012 44 489 495
42. The IAP-antagonist ARTS initiates caspase activation upstream of cytochrome C and SMAC/Diablo. Edison N, Zuri D, Maniv I, Bornstein B, Lev T, Gottfried Y, Kemeny S, Garcia-Fernandez M, Kagan J, Larisch S, Cell Death Differ 2012 19 356 368
43. A novel mitochondrial septin-like protein, ARTS, mediates apoptosis dependent on its P-loop motif. Larisch S, Yi Y, Lotan R, Kerner H, Eimerl S, Tony Parks W, Gottfried Y, Birkey Reffey S, de Caestecker MP, Danielpour D, Book-Melamed N, Timberg R, Duckett CS, Lechleider RJ, Steller H, Orly J, Kim SJ, Roberts AB, Nat Cell Biol 2000 2 915 921
44. Regulation of the proapoptotic ARTS protein by ubiquitin-mediated degradation. Lotan R, Rotem A, Gonen H, Finberg JP, Kemeny S, Steller H, Ciechanover A, Larisch S, J Biol Chem 2005 280 25802 25810 (Pubitemid 40962290)
45. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. Abbas N, Lucking CB, Ricard S, Durr A, Bonifati V, De Michele G, Bouley S, Vaughan JR, Gasser T, Marconi R, Broussolle E, Brefel-Courbon C, Harhangi BS, Oostra BA, Fabrizio E, Böhme GA, Pradier L, Wood NW, Filla A, Meco G, Denefle P, Agid Y, Brice A, Hum Mol Genet 1999 8 567 574 (Pubitemid 29139969)
46. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. Imai Y, Soda M, Takahashi R, J Biol Chem 2000 275 35661 35664
47. Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin. Tanaka A, Cleland MM, Xu S, Narendra DP, Suen DF, Karbowski M, Youle RJ, J Cell Biol 2010 191 1367 1380
48. The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Corti O, Hampe C, Koutnikova H, Darios F, Jacquier S, Prigent A, Robinson JC, Pradier L, Ruberg M, Mirande M, Hirsch E, Rooney T, Fournier A, Brice A, Hum Mol Genet 2003 12 1427 1437 (Pubitemid 36758455)
49. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. Ko HS, von Coelln R, Sriram SR, Kim SW, Chung KK, Pletnikova O, Troncoso J, Johnson B, Saffary R, Goh EL, Song H, Park BJ, Kim MJ, Kim S, Dawson VL, Dawson TM, J Neurosci 2005 25 7968 7978 (Pubitemid 41254399)
50. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. Narendra D, Tanaka A, Suen DF, Youle RJ, J Cell Biol 2008 183 795 803
51. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J, Cookson MR, Youle RJ, PLoS Biol 2010 8 1000298
52. Targeting mitochondrial dysfunction: role for PINK1 and Parkin in mitochondrial quality control. Narendra DP, Youle RJ, Antioxid Redox Signal 2011 14 1929 1938
53. PINK1- and Parkin-mediated mitophagy at a glance. Jin SM, Youle RJ, J Cell Sci 2012 125 795 799
54. Mechanisms of mitophagy. Youle RJ, Narendra DP, Nat Rev Mol Cell Biol 2011 12 9 14
55. Culling sick mitochondria from the herd. Pallanck LJ, J Cell Biol 2010 191 1225 1227
56. Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Gegg ME, Cooper JM, Chau KY, Rojo M, Schapira AH, Taanman JW, Hum Mol Genet 2010 19 4861 4870
57. Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy. Lee JY, Nagano Y, Taylor JP, Lim KL, Yao TP, J Cell Biol 2010 189 671 679
58. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Wang X, Winter D, Ashrafi G, Schlehe J, Wong YL, Selkoe D, Rice S, Steen J, LaVoie MJ, Schwarz TL, Cell 2011 147 893 906
59. Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Ko HS, Lee Y, Shin JH, Karuppagounder SS, Gadad BS, Koleske AJ, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM, Proc Natl Acad Sci U S A 2010 107 16691 16696
60. 14-3-3eta is a novel regulator of parkin ubiquitin ligase. Sato S, Chiba T, Sakata E, Kato K, Mizuno Y, Hattori N, Tanaka K, EMBO J 2006 25 211 221 (Pubitemid 43077309)
61. ITCH regulates degradation of mutant glucocerebrosidase: implications to Gaucher disease. Maor G, Filocamo M, Horowitz M, Hum Mol Genet 2013 22 1316 1327
62. Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl. Lu J, Chiang J, Iyer RR, Thompson E, Kaneski CR, Xu DS, Yang C, Chen M, Hodes RJ, Lonser RR, Brady RO, Zhuang Z, Proc Natl Acad Sci U S A 2010 107 21665 21670
63. The ubiquitin ligase COP1 is a critical negative regulator of p53. Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, O'Rourke K, Koeppen H, Dixit VM, Nature 2004 429 86 92 (Pubitemid 38620556)
64. Mdm2 promotes the rapid degradation of p53. Haupt Y, Maya R, Kazaz A, Oren M, Nature 1997 387 296 299 (Pubitemid 27220766)
65. Regulation of p53 stability by Mdm2. Kubbutat MH, Jones SN, Vousden KH, Nature 1997 387 299 303 (Pubitemid 27220767)
66. Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1. Laine A, Ronai Z, Oncogene 2007 26 1477 1483 (Pubitemid 46340811)
67. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R, Benchimol S, Cell 2003 112 779 791 (Pubitemid 36378882)